Surgical resection combined with perioperative chemotherapy for a patient with locally recurrent, previously stage <scp>IV</scp> thymic small‐cell carcinoma: A case report

Terada, Junki; Toyoda, Yuko; Takeuchi, Eiji; Tanida, Nobuyuki; Yorita, Kenji; Matsuoka, Hidehito; Bando, Hiroki; Morita, Yutaka; Okamoto, Yuri; Shinohara, Tsutomu

doi:10.1111/1759-7714.14717

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering that if KHE could not be completely resected through surgery, drug chemotherapy was generally recommended (12). There is a case showed that surgical resection combined with chemotherapy is effective for recurrent tumor, even in patients with stage IV cancer (15). Also, in the treatment of hemangiomas, intratumoral injection of bleomycin may have a sclerosing effect on potentially residual or recalcitrant tumor tissue (16).…”

Section: Discussionmentioning

confidence: 99%

Case Report: Recurrent blepharal kaposiform hemangioendothelioma in an adult patient

Liu,

Zhao,

Zhou

et al. 2024

Front. Surg.

View full text Add to dashboard Cite

BackgroundKaposiform hemangioendothelioma (KHE) is a rare and invasive vascular tumor that mainly occurs in children and is rarely seen in adults. We report a case of KHE found on the eyelid of an adult patient.Case reportWe present an adult patient in whom KHE recurred 6 months after tumor resection. He underwent second surgical resection and intraoperative chemotherapy. There was no evidence of recurrence at the 3-year follow-up.ConclusionKHE in adults is easy to be misdiagnosed. KHE can be treated by surgical resection. Complete resection of the tumor and intraoperative chemotherapy may help prevent a recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: Recurrent blepharal kaposiform hemangioendothelioma in an adult patient

Liu,

Zhao,

Zhou

et al. 2024

Front. Surg.

View full text Add to dashboard Cite

show abstract

“…Hiroyuki et al. reported a case with stage IVB thymic carcinoma that radical resection was performed after concurrent chemoradiotherapy and the patient had 30 months of recurrence-free survival ( 25 ); Coincidentally, a clinical team from Japan conducted a cure for a patient with locally recurrent, previously stage IV thymic small-cell carcinoma by surgery combined with perioperative chemotherapy and the tumor did not recur more than 2.5 years ( 26 ). Moreover, a retrospective study from Yusuke concluded that surgical intervention was a favorable factor for overall survival in patients with advanced thymic carcinoma ( 27 ).…”

Section: Discussionmentioning

confidence: 99%

The role of surgery in advanced thymic tumors: A retrospective cohort study

Tian

2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThere is no definitive and detailed treatment guideline for advanced thymic tumors, thus when lymph node and other organ metastasis are present, clinical guidelines recommend chemotherapy-based multidisciplinary treatment. A consensus has been reached that surgery has beneficial effects on partial patients with stage IVA whose metastatic lesions were isolated and resectable, but because of few cases of advanced thymic tumor s and the scarcity of reports, the role of surgery in stage IVB is still unknown. The current study aimed to systematically analyze the role of surgery in advanced thymic tumors based on the Surveillance, Epidemiology, and End Results (SEER) database, with a sufficient number of cases. A secondary aim was to clarify the prognostic value of surgery in advanced thymic tumors.MethodData derived from a total of 979 patients with advanced thymoma or advanced thymic carcinoma were collected from the SEER database. Propensity score matching was performed to eliminate confounding factors, and Cox regression analyses were conducted to assess prognoses.ResultsPatients were assigned to four groups based on pathology and whether surgery was performed; thymoma (surgery), thymoma (no surgery), thymic carcinom a (surgery), and thymic carcinoma (no surgery). Disease-specific survival differed significantly in the thymoma (surgery) and thymoma (no surgery) groups, both before and after propensity score matching (both p < 0.001). Similarly, disease-specific survival differed significantly in the thymic carcinoma (surgery) and the thymic carcinoma (no surgery) groups (p < 0.001 before and p = 0.003 after). No total resection, distant metastasis, and thymic carcinoma were all unfavorable prognostic factors.ConclusionsIn the present study surgery had positive effects on advanced thymoma and advanced thymic carcinoma patients who could undergo surgical resection, significantly improving survival times. Total resection of the primary site was the most advantageous form of surgery. The study provides a reference for the clinical treatment of advanced thymic tumors.

show abstract

“…However, this particular study did not indicate the subtype of TCs. Furthermore, the most recent case 21 reported a patient with advanced thymic SCC with liver metastases, bilateral pleural effusion and pericardial fluid in which all evaluable lesions disappeared after 4 cycles of EC regimen chemotherapy. Six months later, CT scan revealed recurrence of the primary tumor.…”

Section: Discussionmentioning

confidence: 99%

The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundTo provide real‐world outcomes for the combination of etoposide and platinum as a first‐line treatment for advanced thymic neuroendocrine neoplasms (TNENs).MethodsRetrospective analysis was performed on patients with advanced TNENs confirmed by pathology who received etoposide combined with platinum as a first‐line chemotherapy in our institution between 2010 and 2022.ResultsA total of 16 patients were included in this study. Twelve patients (75%) received etoposide combined with cisplatin, and four patients (25%) received etoposide combined with carboplatin. Efficacy was evaluated in all patients, with an objective response rate of 31.3%. One patient achieved a complete response, four achieved a partial response, and in eight patients the disease remained stable; the disease control rate was 81.3%. The median progression‐free survival (PFS) was 7.2 months with a 95% confidence interval (CI) of 2.1–12.3 months. The median overall survival (OS) was 50.4 months with a 95% CI of 32.1–68.8 months. No significant difference in efficacy was observed between the treatment groups with regards to PFS (p = 0.095) and OS (p = 0.061). Treatment‐related adverse events were observed in all 12 patients when evaluated for toxicity, manifesting as hematologic toxicity. Grade 3–4 bone marrow suppression occurred in six patients (50%). No treatment‐related deaths were recorded.ConclusionThis retrospective analysis, conducted in a real‐life setting, suggests that the combination of etoposide and platinum has a promising anti‐tumor activity in advanced TNENs, with a clinically significant overall response rate.

show abstract

Surgical resection combined with perioperative chemotherapy for a patient with locally recurrent, previously stage IV thymic small‐cell carcinoma: A case report

Cited by 4 publications

References 19 publications

Case Report: Recurrent blepharal kaposiform hemangioendothelioma in an adult patient

Case Report: Recurrent blepharal kaposiform hemangioendothelioma in an adult patient

The role of surgery in advanced thymic tumors: A retrospective cohort study

The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis

Contact Info

Product

Resources

About